» Articles » PMID: 35936768

Diagnostic Value of Striatal F-FP-DTBZ PET in Parkinson's Disease

Overview
Specialty Geriatrics
Date 2022 Aug 8
PMID 35936768
Authors
Affiliations
Soon will be listed here.
Abstract

Background: F-FP-DTBZ has been proven as a biomarker for quantifying the concentration of presynaptic vesicular monoamine transporter 2 (VMAT2). However, its clinical application is still limited.

Objectives: To evaluate the difference in dopaminergic integrity between patients with Parkinson's disease (PD) and healthy controls (HC) using F-FP-DTBZ PET and to determine the diagnostic value of standardized uptake value ratios (SUVRs) using the Receiver Operating Characteristic (ROC) curve.

Methods: A total of 34 PD and 31 HC participants were enrolled in the PET/MR derivation cohort, while 89 PD and 18 HC participants were recruited in the PET/CT validation cohort. The Hoehn-Yahr Scale and the third part of the MDS-Unified Parkinson's Disease Rating Scale (MDSUPDRS-III) were used to evaluate the disease staging and severity. All assessments and PET scanning were performed in drug-off states. The striatum was segmented into five subregions as follows: caudate, anterior dorsal putamen (ADP), anterior ventral putamen (AVP), posterior dorsal putamen (PDP), and posterior ventral putamen (PVP) using automatic pipeline built with the PMOD software (version 4.105). The SUVRs of the targeted subregions were calculated using the bilateral occipital cortex as the reference region.

Results: Regarding the diagnostic value, ROC curve and blind validation showed that the contralateral PDP (SUVR = 3.43) had the best diagnostic accuracy (AUC = 0.973; < 0.05), with a sensitivity of 97.1% (95% CI: 82.9-99.8%), specificity of 100% (95% CI: 86.3-100%), positive predictive value (PPV) of 100% (95% CI: 87.0-100%), negative predictive value (NPV) of 96.9% (95% CI: 82.0-99.8%), and an accuracy of 98.5% for the diagnosis of PD in the derivation cohort. Blind validation of F-FP-DTBZ PET imaging diagnosis was done using the PET/CT cohort, where participants with a SUVR of the PDP <3.43 were defined as PD. Kappa test showed a consistency of 0.933 ( < 0.05) between clinical diagnosis and imaging diagnosis, with a sensitivity of 98.9% (95% CI: 93.0-99.9%), specificity of 94.4% (95% CI: 70.6-99.7%), PPV of 98.9% (95% CI: 93.0-99.9%), NPV of 94.4% (95% CI: 70.6-99.7%), and a diagnostic accuracy of 98.1%.

Conclusions: Our results showed that an SUVR threshold of 3.43 in the PDP could effectively distinguish patients with PD from HC.

Citing Articles

The combination of F-fluorodeoxyglucose and F 9-fluoropropyl-(+)-dihydrotetrabenazine positron emission tomography for distinguishing between early-onset and late-onset idiopathic Parkinson disease and analyzing influencing factors.

Li S, Lu W, Yan S, Song T, Zhang C, Yang C Quant Imaging Med Surg. 2024; 14(10):7406-7419.

PMID: 39429607 PMC: 11485372. DOI: 10.21037/qims-24-804.


Positron Emission Tomography Imaging of Synaptic Dysfunction in Parkinson's Disease.

Niu J, Zhong Y, Jin C, Cen P, Wang J, Cui C Neurosci Bull. 2024; 40(6):743-758.

PMID: 38483697 PMC: 11178751. DOI: 10.1007/s12264-024-01188-0.


Parkinson's disease and comorbid myasthenia gravis: a case report and literature review.

Zhang Q, Xu E, Li H, Chan P, Zhao Z, Ma J Front Neurol. 2024; 14:1303434.

PMID: 38259657 PMC: 10800518. DOI: 10.3389/fneur.2023.1303434.


Brain microglia activation and peripheral adaptive immunity in Parkinson's disease: a multimodal PET study.

Liu S, Qiao H, Song T, Liu X, Yao Y, Zhao C J Neuroinflammation. 2022; 19(1):209.

PMID: 36038917 PMC: 9422161. DOI: 10.1186/s12974-022-02574-z.

References
1.
Adler C, Beach T, Hentz J, Shill H, Caviness J, Driver-Dunckley E . Low clinical diagnostic accuracy of early vs advanced Parkinson disease: clinicopathologic study. Neurology. 2014; 83(5):406-12. PMC: 4132570. DOI: 10.1212/WNL.0000000000000641. View

2.
Okamura N, Villemagne V, Drago J, Pejoska S, Dhamija R, Mulligan R . In vivo measurement of vesicular monoamine transporter type 2 density in Parkinson disease with (18)F-AV-133. J Nucl Med. 2010; 51(2):223-8. DOI: 10.2967/jnumed.109.070094. View

3.
de la Fuente-Fernandez R . Role of DaTSCAN and clinical diagnosis in Parkinson disease. Neurology. 2012; 78(10):696-701. DOI: 10.1212/WNL.0b013e318248e520. View

4.
Pontone G, Williams J, Anderson K, Chase G, Goldstein S, Grill S . Prevalence of anxiety disorders and anxiety subtypes in patients with Parkinson's disease. Mov Disord. 2009; 24(9):1333-8. PMC: 2830642. DOI: 10.1002/mds.22611. View

5.
Lin S, Lin K, Hsiao I, Hsieh C, Lin W, Lu C . In vivo detection of monoaminergic degeneration in early Parkinson disease by (18)F-9-fluoropropyl-(+)-dihydrotetrabenzazine PET. J Nucl Med. 2013; 55(1):73-9. DOI: 10.2967/jnumed.113.121897. View